Prothena Corp Public Ltd Co (PRTA) — SEC Filings
Prothena Corp Public Ltd Co (PRTA) — 42 SEC filings. Latest: 8-K (May 7, 2026). Includes 19 8-K, 8 SC 13G/A, 5 10-Q.
View Prothena Corp Public Ltd Co on SEC EDGAR
Overview
Prothena Corp Public Ltd Co (PRTA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Prothena Corporation plc announced on December 10, 2025, the departure of Dr. Genevieve L. Cox from her role as Chief Medical Officer. Concurrently, the company appointed Dr. Sarah L. Galvin as the new Chief Medical Officer. Dr. Galvin's compensation arrangements are detailed in this filing.
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 39 neutral. The dominant filing sentiment for Prothena Corp Public Ltd Co is neutral.
Filing Type Overview
Prothena Corp Public Ltd Co (PRTA) has filed 19 8-K, 2 DEFA14A, 3 DEF 14A, 5 10-Q, 2 10-K, 8 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of PRTA's 29 recent filings, 1 were flagged as high-risk, 12 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2.0M |
| Net Income | -$66.7M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $426.0M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Genevieve L. Cox
- Dr. Sarah L. Galvin
- Daniel G. Welch
- Gene G. Kinney Ph.D.
- Michael J. Malecek
- Dr. Jeffrey M. Stein
- Dr. Sarah L. Hough
- Dr. Michael R. Mercali
- Dr. Genevieve Nelson
- Dr. Tracey L. Weiler
- Dr. Amina Khan
- Dr. Jonathan Venner
- Richard T. Collier
- Shane M. Cooke
- William H. Dunn, Jr.
Industry Context
Prothena operates in the biotechnology sector, focusing on developing therapies for rare diseases. This industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies often rely on strategic financial maneuvers, such as capital adjustments, to fund ongoing research and development or to return value to shareholders.
Top Tags
corporate-governance (6) · sec-filing (6) · 10-Q (4) · financial-reporting (3) · 8-k (3) · pharmaceuticals (3) · financials (3) · institutional-ownership (3) · corporate-update (2) · Clinical Trials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Date of Extraordinary General Meeting | November 19, 2025 | Shareholders will vote on capital reduction |
| Time of EGM | 4:00 p.m. local time | Meeting will be held in Dublin, Ireland |
| Record Date for EGM | September 24, 2025 | Shareholders owning shares on this date can vote |
| Ordinary shares issued and outstanding | 53,829,928 | Total shares eligible to vote as of Record Date |
| Ordinary shares required for quorum | 26,914,965 | Represents a majority of issued and outstanding shares |
| Approval threshold for Proposal No. 1 | 75% | Required percentage of votes cast for special resolution |
| Par value per ordinary share | $0.01 | Nominal value of Prothena's shares |
| Date of press release | August 4, 2025 | Referenced potential share redemption program |
| Proxy Statement availability date | October 7, 2025 | Materials made available to shareholders |
| Proxy voting deadline | November 18, 2025 | 11:59 p.m. Eastern Time for internet/telephone/written proxy |
| Net Loss | $66.7M | Increased from $49.8M in prior-year period, indicating higher operational burn. |
| Total Revenue | $2.0M | Decreased 20% from $2.5M in 2024, reflecting lower collaboration revenue. |
| Cash and Cash Equivalents | $426.0M | Slightly up from $423.0M at year-end 2024, providing liquidity for R&D. |
| Revenue Decrease | 20% | Percentage drop in total revenue from 2024 to 2025 for the six-month period. |
| Reporting Periods | 2020-2024 | Covers multiple fiscal years for financial data and equity awards. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant ownership stake in Prothena Corp PLC.","entity":"FMR LLC","targetDate":"Next 12-18 months","confidence":"high"}
- {"claim":"Prothena Corp PLC's stock price will likely not see significant volatility directly from this filing.","entity":"PROTHENA CORP PUBLIC LTD CO","targetDate":"Short-term (next 1-2 weeks)","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Prothena Corp Public Ltd Co (PRTA)?
Prothena Corp Public Ltd Co has 42 recent SEC filings from Jan 2024 to May 2026, including 19 8-K, 8 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PRTA filings?
Across 42 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 39 neutral. The dominant sentiment is neutral.
Where can I find Prothena Corp Public Ltd Co SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Prothena Corp Public Ltd Co (PRTA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Prothena Corp Public Ltd Co?
Key financial highlights from Prothena Corp Public Ltd Co's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PRTA?
The investment thesis for PRTA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Prothena Corp Public Ltd Co?
Key executives identified across Prothena Corp Public Ltd Co's filings include Dr. Genevieve L. Cox, Dr. Sarah L. Galvin, Daniel G. Welch, Gene G. Kinney Ph.D., Michael J. Malecek and 11 others.
What are the main risk factors for Prothena Corp Public Ltd Co stock?
Of PRTA's 29 assessed filings, 1 were flagged high-risk, 12 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Prothena Corp Public Ltd Co?
Recent forward-looking statements from Prothena Corp Public Ltd Co include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in Prothena Corp PLC.","entity":"FMR LLC","targetDate":"Ne and 1 other predictions.